Introduction {#s0010}
============

There is a high prevalence of vitamin D deficiency in the critically ill patient population, with approximately 60% of patients found to be vitamin D deficient, (25(OH)D concentrations \<20 ng/mL), and an additional 30% of patients being vitamin D insufficient, (25(OH)D = 20--30 ng/mL) [@bib0010], [@bib0015], [@bib0020], [@bib0025], [@bib0030], [@bib0035], [@bib0040], [@bib0045], [@bib0050], [@bib0055]. Several intensive care unit (ICU) studies have demonstrated an association between vitamin D deficiency and important clinical outcomes: increased hospital length of stay (LOS), readmission rates, sepsis and mortality [@bib0020], [@bib0025], [@bib0030], [@bib0035], [@bib0040], [@bib0045], [@bib0050], [@bib0060], [@bib0065]. Vitamin D deficiency is also associated with increased risk of acute respiratory failure in critically ill patients [@bib0070], [@bib0075]. Furthermore, Dancer et al. found that vitamin D deficiency is nearly universal in the development of acute respiratory distress syndrome and mechanistically related to lung inflammation and alveolar epithelial cell injury [@bib0080].

Vitamin D has pleiotropic effects on the host immune pathway and may be uniquely involved with lung immune function and alveolar capillary barrier function. In monocytes and macrophages, pathogens bind to cell surface toll-like receptors to CYP27b1 stimulate to convert 25(OH)D, the biomarker of vitamin D status, into the active form 1,25-dihydroxyvitamin D \[1,25(OH)~2~D~3~; calcitriol\]. 1,25(OH)~2~D~3~ in turn upregulates mRNA expression of human cationic antimicrobial protein (hCAP-18), which is cleaved to produce LL-37, a major anti-microbial peptide (AMP) with activity against gram-positive/gram-negative bacteria, fungi and viruses [@bib0085], [@bib0090], [@bib0095]. Although data are inconsistent, existing evidence suggests that supplementation with vitamin D~3~ may decrease susceptibility or enhance recovery to infections such as influenza, recurrent pneumonia and tuberculosis [@bib0100], [@bib0105], [@bib0110].

An observational study in patients with serum 25(OH)D \< 20 ng/ml found that improved vitamin D status before hospital admission decreased the odds of all cause-mortality [@bib0115]. A recent large randomized study by Amrein et al. demonstrated decreased mortality in a subgroup of subjects with severe vitamin D deficiency (\<12 ng/ml) given a one-time bolus dose of 540,000 IU of enteral cholecalciferol [@bib0120]. Leaf et al. found that lower plasma 25(OH)D levels on admission to the ICU correlated with lower LL-37 plasma levels that were, in turn, associated with increased 90 day mortality and sepsis risk [@bib0125], [@bib0130]. In addition, a single intravenous dose of 2 µg calcitriol in adult ICU patients with severe sepsis or shock significantly upregulated leukocyte mRNA for hCAP-18 and the anti-inflammatory cytokine interleukin-10 24 hours after dosing [@bib0125], [@bib0135]. Therefore AMPs may be important modifiers of the immune response in critically ill patients in response to vitamin D status or exogenous administration.

We designed this pilot study to evaluate the safety and efficacy of two doses of vitamin D~3~, 250,000 or 500,000 IU, given in divided doses over 5 consecutive days to increase plasma 25(OH)D concentrations to the sufficient range (\>30 ng/mL) and to increase plasma LL-37 in adult ventilated patients requiring intensive care.

Methods {#s0015}
=======

Trial design {#s0020}
------------

The study was approved by the Emory University Institutional Review Board and written informed consent was obtained from the patient or legal surrogate prior to study enrollment. The enrollment goal of this pilot study was 36 patients (12 in each group) from two Atlanta, Georgia hospitals; Emory University Hospital (EUH) and Emory University Midtown (EUH-M). The study was registered at [www.clinicaltrials.gov](http://www.clinicaltrials.gov){#iw0010} (NCT01372995) and the protocol was amended to include bronchoscopy at both baseline and study day 7. A Data Safety Monitoring Board reviewed progress and adverse event reports every 6 months during the duration of the trial. The entire study duration was 84 days; however, blood samples were only taken every 7 days while the patient was hospitalized.

Participant selection {#s0025}
---------------------

Enrollment started in July 2011 and was completed in March 2014. Inclusion criteria were: 1) receiving care in an ICU; 2) age greater than 18 years; 3) expected to require mechanical ventilation for at least 72 hours after study entry; 4) expected to survive and remain in the ICU for at least 96 hours after study entry; and 5) enteral access in place to enable delivery of vitamin D~3~ or placebo and are deemed to be able to tolerate enteral drug administration. Exclusion criteria were: 1) inability to obtain or declined informed consent from the subject and/or legally authorized representative; 2) current pregnancy; 3) ongoing shock, \[defined as unstable blood pressure despite vasopressor support and mean arterial pressure (MAP) \< 60 mm Hg on at least 3 consecutive readings within a 3-hour period prior to study entry\]; 4) current hypercalcemia (albumin-corrected serum calcium \> 10.8 mg/dL or ionized calcium \> 5.2 mg/dL); 5) history of therapy with high-dose vitamin D~3~ (greater than or equal to 50,000 IU a week) to treat vitamin D deficiency, within previous 6 months; 6) history of disorders associated with hypercalcemia (history of cancer with history of hypercalcemia within the past 1 year, hyperparathyroidism, sarcoidosis, nephrolithiasis); 7) chronic dialysis; 8) known history of cirrhosis; 9) known HIV; and 10) received any investigational drug within 60 days prior to study entry. The initial protocol included bronchoscopy on day 7 of intubation, but the protocol was amended to include a baseline bronchoscopy and then a repeat on days 5--7 if the patient remained intubated, in order to increase our sample size. The protocol was amended in January 2012 to permit enrollment of any adult critically ill mechanically ventilated patients.

Intervention {#s0030}
------------

Following informed consent, subjects\' Acute Physiology and Chronic Health Evaluation II (APACHE II) scores were calculated [@bib0140]. Treatment assignments were stratified according to clinical center and dichotomized APACHE II score ≤ or \>15. Subjects were randomly assigned in a 1:1:1 ratio to placebo or a total of 250,000 IU vitamin D~3~ or 500,000 IU vitamin D~3~ in divided equal doses over 5 days.

Treatment groups were assigned by a blinded block randomization schedule overseen by biostatisticians of the Atlanta Clinical and Translational Science Institute (ACTSI) biostatistics core. The placebo arm received two inactive medication tablets daily for 5 days; treatment arm 1 received one 50,000 international units (IU) of vitamin D~3~ and 1 placebo pill daily for 5 days (250,000 IU total) and treatment arm 2 received 2 pills of 50,000 IU of vitamin D~3~ daily for 5 days (500,000 IU total). The medications were dissolved in sterile water and administered through an enteral feeding tube. Cholecalciferol 50,000 IU tablets were manufactured from Tischon (Westbury, NY) and Biotech (Fayetteville, AR) and bioavailability testing conducted during the trial showed the capsules to be within 10% of the stated dose. EUH and EUH-M Investigational Drug Service pharmacists maintained the code and delivered all study drugs to the respective study subject\'s primary nurses for administration per research protocol. With the exception of the pharmacists, all study staff were blinded to the group allocation.

Clinical and demographic characteristics {#s0035}
----------------------------------------

Clinical and demographic data were collected at baseline. Sequential organ failure assessment (SOFA) [@bib0145] scores, laboratory values and other clinical data were collected daily while the subjects were hospitalized. Hospital-acquired infections (HAI) were measured as a composite of all infectious complications that occurred during hospitalization according to the 2009 Center Disease Control definitions [@bib0150]. Measured safety parameters included serial serum creatinine, calcium, and phosphorous concentrations, and adverse events.

Biospecimen collection {#s0040}
----------------------

Twenty milliliters of venous blood was collected at baseline and again at 7 and 14 days. The bronchoalveolar lavage procedure was performed by serial instillation of 30 mL aliquots of normal saline into a pulmonary subsegment and BALF was collected by suction. BALF was centrifuged (1000 rpm; 15 min) and supernatant frozen at −80 °C. BALF was concentrated 5- to 10-fold for 25(OH)D determinations. Plasma 25(OH)D was measured using a chemiluminescent-based automated machine (IDS-iSYS; Immunodiagnostic Systems, Scottsdale, AZ). The Emory Vitamin D laboratory participates in the Vitamin D External Quality Assessment Scheme and NIST/NIH Vitamin D Metabolites Quality Assurance Program. The 25(OH)D assay also included internal control samples with known 25(OH)D concentrations as an additional quality measure. Plasma LL-37 was determined by ELISA (Hycult Biotech Inc., Plymouth Meeting, PA) and corrected according to BALF urea concentrations.

Sample size and statistical methods {#s0045}
-----------------------------------

The primary outcome was the change in plasma 25(OH)D from baseline to 7 days. Using our preliminary data [@bib0010], 12 subjects in each group were required to test the hypothesis that high-dose vitamin D~3~ would achieve plasma 25(OH)D levels ≥ 30 ng/mL with power of 0.94 and α of 0.05. The primary analysis was according to intent-to-treat and global tests based on a generalized linear models, to estimate the effect of time and treatment on the outcomes. Multiple pairwise comparisons were used to test the difference between groups. In addition, the proportion of patients in each group achieving 25(OH)D levels of \> 30 ng/mL was compared using an uncorrected chi-squared statistic. For outcomes that were not normally distributed, such as ICU LOS and hospital LOS, log-transformation was performed. Correlations were calculated using Spearman\'s rho (ρ). p values \< 0.05 are considered significant. Based upon our previous data on plasma LL-37 levels in adult ICU patients, enrolling 12 subjects per group provided 99% power to detect an increase in LL-37 to levels in normal healthy subjects (27.2 ng/mL) [@bib0010]. Planned secondary outcomes were hospital LOS, development and/or persistence of organ dysfunction quantified using the SOFA score, duration of mechanical ventilation, hospital mortality, mortality at 12 weeks, and HAI.

Results {#s0050}
=======

A total of 31 subjects were enrolled before project funding was ended. Study enrollment, randomization and follow-up are shown in the CONSORT diagram ([Fig. 1](#f0010){ref-type="fig"}). Of 658 patients screened for inclusions/exclusion criteria, a total of 31 subjects were eligible and randomized, and data from 30 subjects were analyzed. Per spousal request, one patient withdrew from the study after completion of study medication. All subjects received all study medication except one subject who received the first day of study drug before a decision was made for comfort care; this individual was included in the assigned intention-to-treat group. No subjects were lost to follow-up. Baseline demographic and clinical characteristics were comparable across all three groups ([Table 1](#t0010){ref-type="table"}). At baseline, comorbidities, including history of heart failure, chronic obstructive pulmonary disease, chronic kidney disease, diabetes, asthma and diagnosis of acute infection did not differ between groups. A history of coronary artery disease was different between groups at baseline; 10.0% (1/10) in the placebo group, 22.2% (2/9) in the 250,000 IU vitamin D~3~ group, and 45.5% (7/10) in the 500,000 IU vitamin D~3~ group, (p = 0.03).Figure 1CONSORT diagram of study subject enrollment, allocation and follow-up.Table 1Baseline demographic characteristicsVariablesPlaceboVitamin D~3~ 250,000 IUVitamin D~3~ 500,000 IUp-valueN = 10N = 9N = 11Female N (%)4(40.0)4(44.4)3(27.3)0.72Race African American4(40.0)7(77.8)3(27.3)0.09 Caucasian5(50.0)2(22.2)8(72.7) American Indian/Alaskan1(10.0)0(0)0(0)Age, mean(SD)64.8(17.5)56.4(15.4)68.1(18.6)0.22BMI, mean(SD)28.2(9.9)33.4(6.3)30.2(6.1)0.62APACHE II, mean(SD)23.2(8.8)20.0(10.1)19.0(7.5)0.55SOFA Day 0, mean(SD)8.6(4.3)8.9(3.6)9.1(3.1)0.47Infection on admission6(60.0)4(44.4)3(27.3)0.38Admission ICU Surgical3(30.0)5(55.6)8(72.7)0.16 Medical7(70.0)4(44.4)3(27.3)Baseline 25(OH)D(ng/mL), mean(SD)21.5(12.2)23.2(7.8)20.0(7.3)0.75Baseline 25(OH)D category Deficient(\<20 ng/mL)5(50.0)3(33.3)5(45.5)0.87 Insufficient(20--30 ng/mL)3(30.0)4(44.4)5(45.5) Sufficient(\>30 ng/mL)2(20.0)2(22.2)1(9.1)Baseline 25(OH)D BALF, mean(SD)14.6(9)13(7)10.4(2)0.63[a](#tn0015){ref-type="table-fn"}Baseline plasma LL-37 ng/mL, median(25%--75%IQR)58.445.557.9(37.2,97.3)(41.2,76.6)(37.1,284.2)0.42Baseline LL-37 BALF(ng/mL) mean(SD)1(1.0)4.90.4(0.4)0.17[b](#tn0020){ref-type="table-fn"}Coronary artery disease1(10.0)2(22.0)7(64.0)0.03[\*](#tn0010){ref-type="table-fn"}Congestive heart failure1(10.0)2(22.0)5(45.5)0.20Diabetes4(40.0)1(11.0)2(18.0)0.32COPD2(20.0)1(11.0)4(36.0)0.49Asthma1(10.0)1(11.0)0(0)0.52[^2][^3][^4][^5]

Measurements of 25(OH)D {#s0055}
-----------------------

On the day of enrollment, 43% of subjects were vitamin D deficient with plasma 25(OH)D levels \< 20 ng/mL and 40% were vitamin D insufficient, defined as plasma 25(OH)D levels 20--30 ng/mL (both similar between groups). Baseline 25(OH)D in BALF did not differ between treatment groups ([Table 1](#t0010){ref-type="table"}). Plasma concentrations of 25(OH)D significantly increased from baseline in both vitamin D~3~ treatment groups at study day 7 (to 45 ± 20 ng/mL in the 250,000 IU and 55 ± 14 ng/mL in the 500,000 IU vitamin D~3~ treatment groups, respectively; each p \< 0.001) ([Fig. 2](#f0015){ref-type="fig"}). The mean change from baseline to day 7 in 25(OH)D levels within groups over time was 0.4 ± 7 ng/mL in the placebo group versus 26 ± 13 ng/mL and 33 ± 16 ng/mL in the 250,000 IU and 500,000 IU vitamin D~3~ treatment groups, respectively, (p \< 0.001).Figure 2Plasma 25-hydroxyvitamin D concentrations by group over time. At study entry the mean plasma 25(OH)D was similar across all groups. By day 7, mean plasma 25(OH)D concentrations significantly increased in the vitamin D treatment groups compared to placebo, with sustained effects up to day 28. There was no statistical difference in the mean plasma 25(OH)D concentration between the 250,000 IU vitamin D~3~ group and the 500,000 IU vitamin D~3~ group.

Measurements of LL-37 {#s0060}
---------------------

Plasma LL-37 levels on day 7 for placebo, 250,000 IU and 500,000 IU were 62.04 ng/mL (IQR 48.56,103.02), 63.16 ng/mL (IQR 47.26,72.14) and 112.3 ng/mL (IQR 63.88,229.22), p = 0.42, respectively. There was no statistically significant change in plasma levels of LL-37 from baseline by group over time (days 7 and 14 after entry) and no correlation with plasma 25(OH)D levels in plasma ([Table 2](#t0015){ref-type="table"}). There was no significant correlation between plasma 25(OH)D, BALF 25(OH)D, plasma LL-37 and BALF LL-37, except for a negative correlation between plasma 25(OH)D concentrations and BALF 25(OH)D concentrations across all groups over time Spearman ρ = −0.59, (p = 0.001) ([Table 3](#t0020){ref-type="table"}).Table 2Change of plasma LL-37 overtime by groupsPlacebo (ng/mL)Vitamin D~3~ 250,000 IU (ng/mL)Vitamin D~3~ 500,000 IU (ng/mL)p valueTotal number of observationsN = 9N = 7N = 9Change of plasma LL-37 day 7 compared to baseline, median (IQR)−3.8\
(−18.9, 26.9)6.0\
(−13.4, 39.2)−13.5\
(−48.4, 37.4)0.42Total number of observationsN = 8N = 6N = 5Change of plasma LL-37 day 14 compared to baseline, median (IQR)1.1\
(−24.6, 10.8)−12.3\
(−36.1, 8.1)−6.0\
(−27.3, 2.0)0.29Table 3Spearman correlation of 25-hydroxyvitamin D between plasma and bronchoalveolar lavage fluid by treatment group and all subjectsPlaceboVitamin D~3~ 250,000 IUVitamin D3 500,000 IUAllSpearman coefficient−0.26−0.87−0.76−0.59p value0.470.05**0.03**[\*](#tn0025){ref-type="table-fn"}**\<0.001**[\*](#tn0025){ref-type="table-fn"}[^6]

Clinical outcomes {#s0065}
-----------------

There was a difference in hospital LOS between groups; placebo 36 ± 19 days compared to 250,000 IU group 25 ± 14 days compared to 500,000 IU group 18 ± 11 days, (p = 0.03) with no statistical differences in ICU LOS or duration of mechanical ventilation ([Table 4](#t0025){ref-type="table"}). Changes in daily SOFA score, frequency of hospital-acquired infections and hospital mortality were similar between groups ([Table 4](#t0025){ref-type="table"}).Table 4Clinical outcomesPlaceboVitamin D~3~ 250,000 IUVitamin D~3~ 500,000 IUp-value group by dayHospital length of stay days, mean (SD)36(19)25(14)18(11)**0.03**[\*](#sp0070){ref-type="fn"}ICU length of stay days, mean (SD)23(14)17(14)15(10)0.30Ventilator days, mean (SD)20(15)12(10)14(10)0.29Change in SOFA score from baseline, mean (SD)−2(3)−3(3)−2(3)0.72Hospital acquired infection, N (%)3(30)3(33)2(18)0.77Hospital mortality, N (%)1 (10)01(10)0.76Day 84 mortality, N (%)2(20)1(11)4(36)0.33[^7]

Safety and adverse events {#s0070}
-------------------------

Mean serum calcium, creatinine and phosphorus concentrations determined during each subject\'s hospitalization stay were similar between groups at all time points. There was no significant rise in calcium, creatinine and phosphorus per patient during the entire study period ([Table A1](#t0030){ref-type="table"}). There was no difference in adverse events between groups. Two subjects were re-hospitalized within 30 days of drug discontinuation and those events were deemed to not be related to study drug.

Discussion {#s0075}
==========

In critically ill patients with respiratory failure, this randomized, controlled, double blind, pilot study demonstrated that either of two high-dose vitamin D~3~ treatment regimens, given orally in divided doses over a 5-day period, safely increased plasma 25(OH)D to \>30 ng/mL by day 7, which was sustainable at least through day 28. These pilot data suggest that high-dose vitamin D~3~ supplementation favorably influenced hospital LOS, complementing the recent findings of Quraishi et al. that serum 25(OH)D levels were inversely associated with hospital LOS in surgical ICU patients [@bib0035]. From a safety perspective, high-dose vitamin D supplementation was well tolerated and without significant adverse events in these critically ill and mechanically ventilated patients.

This pilot study adds to the currently limited literature of high dose vitamin D therapy in critically ill patients, particularly by focusing on critically ill and mechanically ventilated patients without other major comorbidities, as an important test population within the larger population of patients with respiratory failure. In comparison, the VITdAL-ICU clinical trial administered 540,000 IU of vitamin D~3~ as a one-time enteral dose followed by a monthly oral dose of 90,000 IU over 5 months to mixed medical and surgical ICU patients [@bib0155].Clinical outcomes were unaffected except for the subgroup of patients with the lowest 25(OH)D levels (\<12 ng/mL) in which hospital mortality was significantly decreased [@bib0155]. Our study differed from this previous important study in that VITdAL-ICU targeted hospitalized subjects who had documented 25(OH)D levels less than 20 ng/mL, and only 65% of the VITdAL-ICU patients were mechanically ventilated, in contrast to our study, which focused on mechanically ventilated patients without vitamin D status eligibility requirements. Another similar study is that of Quraishi et al. who administered 200,000 IU or 400,000 IU of vitamin D~3~ in critically ill patients with sepsis and also found no correlation between 25(OH)D and LL-37 [@bib0160]. In addition, baseline plasma 25(OH)D were similar in both studies, although Quraishi\'s post-treatment plasma 25(OH)D and LL-37 concentrations were lower than in the current study.

Despite a rapidly growing body of scientific literature, the mechanisms underlying the potential benefit of high-dose vitamin D therapy remain uncertain. Several epidemiologic studies have shown an association between vitamin D deficiency and increased risk of respiratory infections [@bib0165], [@bib0170] as well as an direct relationship between vitamin D and decreased lung function in patients with chronic obstructive pulmonary disease and interstitial lung disease [@bib0175], [@bib0180], [@bib0185], [@bib0190]. Therapeutically, administration of 25(OH)D was associated with an increase in lung function for adult patients with asthma [@bib0195] and with improved one year survival in patients with cystic fibrosis [@bib0200]. Given that vitamin D may uniquely impact lung function, it is possible that therapeutic benefits of high dose vitamin D~3~ may be particularly evident in critically ill patients with respiratory failure, but this would need to be tested in a rigorous clinical trial.

Limitations of this randomized clinical trial were the small sample size, imbalances in chronic conditions between treatment groups at study entry and the relatively low rate of infection in the cohort. In addition, out of 658 patients screened we enrolled only 31 subjects and caution the generalizability of our results. Also, we did not analyze steroid use and may be an unknown confounding variable and limitation to this study and future studies will need to monitor corticosteroid dosing and duration as a potential confounder. Our study is the first in critically ill patients to administer high-dose vitamin D in divided doses over a period of several days instead of a one-time dose, to ensure adequate medication effect to effectively test our hypotheses, as critically ill patients often have gastrointestinal intolerance and variable drug absorption. The randomized nature of the study design, with control for disease severity in the randomization scheme, strengthens the results, although we interpret the clinically important improvements in hospital LOS with caution due to the risk of type I error in a pilot study. Our results regarding LL-37 differ from Nair et al. [@bib0205], who found an increase in serum 25(OH)D concentrations associated with increased serum LL-37 on days 1 and 3 in critically ill patients treated with cholecalciferol, raising the possibility that LL-37 regulation is time dependent within the first few days of vitamin D therapy and was not reflected in our measurements at day 7 [@bib0205].

Currently, clinical practice guidelines do not exist regarding therapeutic dosing of vitamin D in critically ill patients. The growing body of literature suggests potentially important clinical benefits, such as for hospital LOS and survival, particularly for those critically ill patients with the lowest serum 25(OH)D and with infections or respiratory failure. High-dose vitamin D may have multifactorial effects that could contribute directly or indirectly to hospital LOS, including salutary effects, via improved 25(OH)D levels on respiratory or other skeletal muscle function, by modulation of the pro-inflammatory milieu, and by regulation of immune functions, among other contributors [@bib0210]. Therefore, there may be additional musculoskeletal effects that are unknown at this time, such as positive sub-acute effects that facilitated musculoskeletal recovery and thus expedited hospital discharge. Additional studies are needed to define the putative mechanisms underlying such benefits, and to clearly determine the clinical outcome benefits of high-dose vitamin D~3~ therapy.

Clinical trial registration {#s0080}
===========================

[www.clinicaltrials.gov](http://www.clinicaltrials.gov){#iw0015} (NCT01372995).
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Appendix {#s0095}
========

Table A1Average blood calcium, creatinine, and phosphorus for all patients by groupGroupp-valuePlaceboVitamin D3 250,000 IUVitamin D3 500,000 IUMean calcium mg/dL mean (SD)8.33 (0.75)8.40 (0.52)8.41 (0.63)0.95Mean creatinine mg/dL mean (SD)2.15 (1.41)2.21 (3.13)1.51 (0.83)0.67Mean phosphorus mg/dL mean (SD)3.26 (1.40)4.22 (1.80)4.03 (0.88)0.28
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[^1]: Contributed equally to this work.

[^2]: 25(OH)D, 25 hydroxyvitamin D; BALF, bronchial alveolar lavage fluid; COPD, chronic obstructive pulmonary disease; IQR, interquartile range.

[^3]: p \< 0.05 statistically significant.

[^4]: Placebo N = 7; 250,000 N = 5, 500,000 N = 7.

[^5]: Placebo N = 4; 250,000 N = 1, 500,000 N = 1.

[^6]: p values of \<0.05 are considered statistically significant.

[^7]: N = 30, \*p \< 0.05, p-value interaction between group and time, length of stay log transformed.
